Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 4/20 | 0.39 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.39 |
| ▸ | CDK1 | P06493 | 3/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.39 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.39 |
| ▸ | CACNG8 | Q8WXS5 | 2/20 | 0.39 |
| ▸ | AHR | P35869 | 4/20 | 0.39 |
| ▸ | CMA1 | P23946 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12992123 | 0.81 | GRIA1 (0.41) | CA9GSK3BCCNB2CDK1CCNB1 | |
| SCHEMBL25746058 | 0.81 | GSK3B (0.38) | GSK3BCCNB2CDK1CCNB1CDK5 | |
| SCHEMBL10130338 | 0.81 | AHR (0.44) | MMP12GSK3BCCNB2CDK1CCNB1 | |
| SCHEMBL5246021 | 0.81 | CMA1 (0.41) | MMP12GSK3BCCNB2CDK1CCNB1 | |
| SCHEMBL5789814 | 0.81 | GSK3B (0.38) | CA9MMP12GSK3BCCNB2CDK1 | |
| SCHEMBL31383739 | 0.81 | CMA1 (0.41) | MMP12GSK3BCCNB2CDK1CCNB1 | |
| SCHEMBL9834730 | 0.78 | GSK3B (0.42) | GSK3BCCNB2CDK1CCNB1CDK5 | |
| SCHEMBL10129810 | 0.77 | POLB (0.37) | MMP12GSK3BCCNB2CDK1CCNB1 | |
| SCHEMBL5789641 | 0.75 | GPR35 (0.44) | GSK3BCCNB2CDK1CCNB1CDK5 | |
| SCHEMBL10714014 | 0.75 | GRIA1 (0.49) | GSK3BCCNB2CDK1CCNB1CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180256543-A1 | SUBSTITUTED 5-HYDROXYOXINDOLES AND THEIR USE AS ANALGESICS AND FEVER REDUCERS | CARAFE DRUG INNOVATION, LLC. | 2018-09-13 | — | — | US | disclosed |
| WO-2016179157-A1 | SUBSTITUTED 5-HYDROXYOXINDOLES AND THEIR USE AS ANALGESICS AND FEVER REDUCERS | CARAFE DRUG INNOVATION, LLC (US) | 2016-11-10 | — | — | WO | disclosed |
| WO-2016179157-A1 | SUBSTITUTED 5-HYDROXYOXINDOLES AND THEIR USE AS ANALGESICS AND FEVER REDUCERS | CARAFE DRUG INNOVATION, LLC (US) | 2016-11-10 | — | — | WO | disclosed |
| EP-1955697-B1 | 2-AMINOBENZAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) INHIBITORS USEFUL FOR THE TREATMENT OF PAIN OR BLADDER FUNCTION DISORDER | ASTELLAS PHARMA INC (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-8106190-B2 | 2-aminobenzamide derivatives | ASTELLAS PHARMA INC. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-8106190-B2 | 2-aminobenzamide derivatives | ASTELLAS PHARMA INC. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-09-17 | — | — | US | disclosed |
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1955697-A1 | 2-AMINOBENZAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-7189721-B2 | Bicyclic protein kinase inhibitors | SUGEN INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189721-B2 | Bicyclic protein kinase inhibitors | SUGEN INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189721-B2 | Bicyclic protein kinase inhibitors | SUGEN INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-6906093-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| US-6683082-B2 | 3-HETERO-ARYLIDENE-2-INDOLINONE COMPOUNDS; ANTICANCER AGENTS | SUGEN, INC. | 2004-01-27 | — | — | US | disclosed |
| US-6486185-B1 | 3-heteroarylidene-2-indolinone protein kinase inhibitors | SUGEN, INC. | 2002-11-26 | — | — | US | disclosed |
| US-6316429-B1 | ENZYME INHIBITORS MODULATE THE ACTIVITY OF PROTEIN KINASES AND THEREFORE ARE EXPECTED TO BE USEFUL IN THE PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED CELLULAR DISORDERS SUCH AS CANCER. | SUGEN, INC. | 2001-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | TRPV1, TRPV2, TRPV5 | CA12 3007/4885CA1 2067/4885CA2 267/4885 |
| US-20180256543-A1 | SUBSTITUTED 5-HYDROXYOXINDOLES AND THEIR USE AS ANALGESICS AND FEVER REDUCERS | NPY5R, NPY1R, MC5R | CA12 3567/4885CA1 1323/4885CA2 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.